Metamizole Could Be Alternative to Classical NSAIDs

This article originally appeared here.
Share this content:
Metamizole Could Be Alternative to Classical NSAIDs
Metamizole Could Be Alternative to Classical NSAIDs

THURSDAY, July 14, 2016 (HealthDay News) -- Metamizole seems to be safer than other nonsteroidal anti-inflammatory drugs (NSAIDs) and causes fewer gastric and duodenal ulcers in postoperative pain management, according to a review published online June 27 in Pain Practice.

Noting that use of metamizole has been discouraged because of the risk for agranulocytosis, Jorieke Konijnenbelt-Peters, M.D., Ph.D., from Canisius Wilhelmina Ziekenhuis in Nijmegen, Netherlands, and colleagues conducted a systematic literature review to examine whether metamizole could be an alternative to classical NSAIDs in postoperative pain management.

The researchers found that there were fewer gastric and duodenal ulcers with metamizole versus other nonselective NSAIDs, with a limited risk of bleeding. It was unknown whether metamizole was safer than a nonselective NSAID together with a proton pump inhibitor. In healthy volunteers, the drug appeared to be safe for renal function, but data were lacking for high-risk patients (such as those with heart or renal failure). The incidence of metamizole-induced agranulocytosis was controversial, but in this selected group of patients, the risk was likely limited to short-term postoperative use.

"Although firm evidence is lacking, metamizole may be safer for the upper intestinal tract and kidneys than other NSAIDs, and could alternatively be used in patients with an increased risk for stomach or renal problems," the authors write. "The risk for metamizole-induced agranulocytosis is judged to be acceptable."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »